Clinical-stage AI company Insilico Medicine has nominated a novel small molecule inhibitor known as ISM9274 as a preclinical candidate for cancer treatment.
The company used its PandaOmics AI platform to analyze genomic data from more than 90 tumor types and identified CDK12 as a promising target for multiple cancers including triple-negative breast cancer, lung cancer, and pancreatic cancer.
Next, it used its AI drug discovery engine Chemistry42 to design ISM9274 to selectively inhibit CDK12 and CDK13. Preclinical studies showed ISM9274 demonstrated potent antiproliferative activity across 60 cancer cell lines representing 13 tumor types. It also showed efficacy in animal models as both monotherapy and in combination with other therapies.
“Our target discovery philosophy is to find an optimal balance between commercial tractability, novelty and confidence,” said Alex Zhavoronkov, founder and CEO of Insilico Medicine.
The company’s AI platfo…